SCHEMBL7597666

SCHEMBL7597666

O=C(OC1CCc2ccccc2O1)c1ccccc1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.54
ALDH1A1 P00352 2/20 0.54
HSD17B10 Q99714 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
KDM4E B2RXH2 1/20 0.54
MAPT P10636 1/20 0.54
PIN1 Q13526 1/20 0.45
CA2 P00918 2/20 0.41
BCHE P06276 5/20 0.41
LMNA P02545 2/20 0.41
CYP3A4 P08684 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
DYRK1A Q13627 1/20 0.39
IGF1R P08069 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
TAS1R2 Q8TE23 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9290880 0.81 SSTR4 (0.45) TSHRCA2DYRK1AIGF1RHPGD
SCHEMBL7336911 0.80 CA2 (0.43) TSHRCA2DYRK1AIGF1RHPGD
SCHEMBL4197198 0.80 CA2 (0.43) TSHRCA2DYRK1AIGF1RHPGD
SCHEMBL5695473 0.79 CA2 (0.46) TSHRCA2HPGD
SCHEMBL6493103 0.79 GABRA1 (0.47) TSHRCA2HPGD
SCHEMBL9379705 0.79 CA2 (0.43) TSHRALDH1A1HSD17B10TDP1CA2
SCHEMBL12038566 0.75 CA2 (0.40) TSHRALDH1A1HSD17B10TDP1CA2
Salicylic Acid SCHEMBL7597669 0.74 ALDH1A1 (0.50) TSHRALDH1A1HSD17B10TDP1KDM4E
SCHEMBL12038576 0.74 CA2 (0.39) TSHRPIN1CA2HPGD
SCHEMBL7867727 0.73 CYP4F2 (0.45) TSHRALDH1A1HSD17B10TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6498191-B2 FOR TREATMENT OF ALZHEIMER'S DISEASE, DIABETES MELLITUS, PARKINSON'S DISEASE, NEURONAL AND CARDIAC ISCHEMIA, HUNTINGTON'S DISEASE, STROKE MITOKOR 2002-12-24 US disclosed
US-20020010195-A1 Mitochondria protecting agents for treating mitochondria associated diseases GHOSH SOUMITRA S (US) 2002-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010195-A1 Mitochondria protecting agents for treating mitochondria associated diseases TFAM, HSPA9, HSPD1 TSHR 4712/4885ALDH1A1 945/4885HSD17B10 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.